This is the fourth article in a DeepTech Series by Margaretta Colangelo and Dmitry Kaminskiy. Dmitry Kaminskiy, General Partner at Deep Knowledge Ventures, is based in London. Dmitry is Managing Trustee of the Biogerontology Research Foundation. Margaretta Colangelo, Managing Partner at Deep Knowledge Ventures, is based in San Francisco. Margaretta serves on the Advisory Board of the AI Precision Health Institute at the University of Hawai‘i Cancer Center. Originally posted here.
Source for picture: here
How AI can be used to design personalized prosthetic heart valves
Researchers at Iowa State University designed an AI system to create personalized prosthetic aortic heart valves. These customized valves can restore normal blood flow for people with aortic valvular disease. Over 90,000 people in the US have valve replacement surgery every year.
The first blockbuster drug developed using AI may be here by 2020
Traditional drug discovery is a very long and expensive process involving many tests to determine the safety and efficacy of each new drug candidate. AI is making the hunt for new drugs quicker, cheaper and more effective. Drug companies are already conducting clinical trials for drugs developed using AI, so although no AI for Drug Discovery companies have brought a drug to market yet, we could see the arrival of the AI industry’s first blockbuster drug as early as 2020.
Most healthcare unicorns haven’t published any peer reviewed papers
An analysis of 47 biomedical unicorns found that most of the highest valued startups in healthcare have very limited or non‐existent participation in the publicly available scientific literature. The system of peer reviewed publishing, while imperfect, plays a role in validating innovative products and technologies in biomedicine. Healthcare products not subjected to peer review may be problematic.
Where AI may make the biggest impact in healthcare
On the entire continent of Africa, if you remove Egypt and South Africa, there are only 6 pediatric radiologists. In Liberia there are only 2 radiologists. Fourteen African countries have no radiologists at all. One hospital in Boston, Massachusetts General Hospital, has 126 radiologists. Researchers are working towards extending the reach of care outside of hospitals and clinics. AI will help increase access to care in places where radiologists are inaccessible.
BioPharma must innovate or die
Although Pharma companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials, and 75% of newly approved drugs are unable to cover the cost of development. BioPharma companies capable of building strong AI divisions and acquiring the best AI startups will dominate the biopharma industry and see their market capitalizations skyrocket.
The majority of AI algorithms evaluated did not adequately validate…
Researchers in Korea analyzed literature evaluating 516 AI algorithms for medical image analysis and found that only 6% validated their AI and 0% were ready for clinical use. This lack of appropriate clinical validation is referred to as digital exceptionalism.
Top 100 AI leaders in drug discovery and advanced healthcare
An interactive list of 100 innovative AI leaders who initiating data-driven transformation in the pharmaceutical and healthcare industries. This interactive list is based on assessment of the cumulative impact that each person is contributing to the advancement of AI in the areas of pharmaceutical and healthcare research. The overall success of AI transformation depends on highly skilled interdisciplinary leaders who have the ability to innovate, organize and guide others.
DeepTech in Drug Discovery
One of the sectors most impacted by DeepTech is AI for Drug Discovery. In this article we profile four top tier companies in this sector: Insilico Medicine, Cyclica, Healx, MindsAI. In contrast to other areas of human endeavor, drug discovery has not become faster and cheaper with time. Using AI for drug discovery could help change this.
DeepTech in BioMedicine
Some of the industries most impacted by DeepTech include life sciences, biotech, biomedicine, and Longevity. DeepTech companies are fundamentally different from regular tech companies. Instead of being based on innovative business models, they’re based on cutting edge science and technology that have the potential to cause major disruption across industries. DeepTech companies profiled: The Buck Institute for Research on Aging, Leucadia Therapeutics, Oisin Biotechnologies, Elevian, Insilico Medicine.
This AI system can diagnose 55 childhood diseases better than some …
This AI algorithm can diagnose 55 childhood diseases with 90 to 97% accuracy. This organ-based approach can outperform most doctors at detecting life-threatening conditions like meningitis and sepsis.
DeepTech for Social Good
Scientists at the AI Precision Health Institute at the University if Hawai‘i Cancer Center are using AI to improve the diagnosis and treatment of cancer. They’re collaborating with doctors in underserved communities, enrolling underrepresented populations in clinical studies, and making contributions to science that will benefit our generation and future generations. A prime example of DeepTech for Social Good.
A New Global AI Hub
A new global AI hub officially launched today at Stanford University. The Stanford Institute for Human-Centered AI seeks to become an interdisciplinary global AI hub and to fundamentally change the field of AI by integrating a wide range of disciplines and prioritizing true diversity of thought.
The first AI company to receive FDA clearance for an AI algorithm i…
This software that originated in a Stanford basement is now one of the top AI solutions. Arterys AI software analyzes cardiac MRI exams to show the heart in 7 dimensions: 3 in space, 1 in time, and 3 directions of velocity to show if blood is flowing through the heart the way it should or if there are anomalies that require surgery. Arterys is the first company to receive FDA clearance for an AI algorithm in the cloud.
The 100 leading pioneers of AI for drug development
These 100 AI leaders are initiating data-driven transformation in the pharmaceutical and healthcare industries. The overall success of AI transformation in healthcare depends on highly skilled interdisciplinary leaders who contribute to the advancement of AI in pharmaceutical and healthcare research and also have the ability to innovate, organize and guide others.
Innovative and affordable medical devices to bring healthcare to a …
In India over 100 doctors and engineers have collaborated to develop 40 affordable medical devices to improve healthcare for a billion people. The Biomedical Engineering Technology Incubation Centre at Indian Institute of Technology, Bombay is a center of healthcare innovation.
Paige.AI has being granted breakthrough designation from the FDA
This is the first time that the FDA has granted Breakthrough Designation for AI in cancer diagnosis. This designation will expedite product development and provides priority regulatory review for Paige.AI’s pioneering clinical-grade AI in pathology software.
Could an eye doctor help diagnose Alzheimer’s before a person has s…
New research suggests that loss of blood vessels in the retina could signal Alzheimer’s disease. On the left, the retina of a healthy person shows a dense web of blood vessels. On the right, the retina of a person with Alzheimer’s disease shows areas in blue where blood vessels are less dense. The study was published March 11, 2019 in the journal Ophthalmology Retina.
How AI is revolutionizing the drug industry
AI is revolutionizing the drug industry by cutting development time. AI can save two years in R&D time says Alex Zhavoronkov CEO of Insilico Medicine. Insilico Medicine is turning its focus to China, as it moves its headquarters from US to Hong Kong.
This AI can classify lung cancer as accurately as a pathologist in …
Saeed Hassanpour PhD and his team at Geisel School of Medicine at Dartmouth developed an AI method that improves grading tumor patterns and subtypes of lung cancer and can classify lung cancer subtypes as accurately as a pathologist in less than a minute. They plan to apply this method to analyze images in breast, esophageal, and colorectal cancer.
Using AI to improve the diagnosis and treatment of cancer
Researchers at the AI Precision Heath Institute at the University of Hawaii Cancer Center are using AI to improve the diagnosis and treatment of cancer for hundreds of thousands of people who live in underserved communities on islands in the Pacific.
The FDA is developing new rules for AI in medicine
This white paper describes criteria the FDA proposes to use to determine when AI medical products will require FDA review before being commercialized. The White paper calls for proof in a clinical real world environment. AI algorithms will not be approved on the basis of computerized dataset analysis.
Algorithms can now identify cancerous cells better than humans
AI algorithms are as accurate at analyzing slides as a human pathologist. That’s good because the number of pathologists is declining and increasing disease in an aging population will lead to a deficit of pathologists.
A new active learning method to identify diseases using less data
AI researchers at Carnegie Mellon University developed a highly accurate active learning technique called MedAL that can diagnose disease using much less data. MedAL achieved 80% accuracy detecting diabetic retinopathy – using only 425 labeled images – which is a 40% reduction compared to random sampling. MedAL can also be used to detect skin cancer and breast cancer.
AI can mistakenly see cancer in medical scans after tiny image tweaks
Samuel Finlayson and his team at Harvard Medical School fooled AIs into misclassifying images by altering a few pixels. Rotating images can also confuse AIs. Although AI promises to improve healthcare by quickly analyzing medical scans, there is evidence that it trips up on seemingly innocuous changes. The paper published in Science March 22, 2019 outlines motivations that various entities may have to use adversarial attacks and begin a discussion of what to do about them.
How AI is Finding New Cures in Old Drugs
Since repurposed drugs are already in use, AI for drug discovery companies can skip the Phase I trials normally required to ensure their safety, and eliminate the build from scratch stage. FDA fast-tracking increases the odds that repurposed drugs discovered using AI could be on the market as soon as 2020.
Estimating the age of your brain from MRI data analyzed using AI
Simon Jegou demonstrates the process of creating an algorithm able to estimate the physiological age of the brain of a subject based on MRI data.
China Builds up Muscle in the Pharma AI Race
Chinese investment in US based biotech and pharmaceutical companies increased from $125.5 million in 2017 to $1.4 billion in 2018. The Chinese government is showing significant interest in building up China’s AI industry, and in prioritizing AI in healthcare in particular.
This is the largest AI deal so far according to Exscientia CEO Andr…
Celgene has signed a deal with Exscientia to use Exscientia’s AI for drug discovery expertise to reduce the pre-clinical trial stage of oncology and autoimmunity drug candidates from 5 years to 1 year.
Google’s effort to prevent blindness shows AI challenges
Google developed an AI tool to detect a condition that causes blindness in diabetes patients. Although it worked well in the US, in rural India it didn’t perform well with low-quality images produced by equipment affordable in developing countries.
